170 related articles for article (PubMed ID: 15718226)
1. Cytochrome b mutations that modify the ubiquinol-binding pocket of the cytochrome bc1 complex and confer anti-malarial drug resistance in Saccharomyces cerevisiae.
Kessl JJ; Ha KH; Merritt AK; Lange BB; Hill P; Meunier B; Meshnick SR; Trumpower BL
J Biol Chem; 2005 Apr; 280(17):17142-8. PubMed ID: 15718226
[TBL] [Abstract][Full Text] [Related]
2. Direct evidence for the atovaquone action on the Plasmodium cytochrome bc1 complex.
Siregar JE; Kurisu G; Kobayashi T; Matsuzaki M; Sakamoto K; Mi-ichi F; Watanabe Y; Hirai M; Matsuoka H; Syafruddin D; Marzuki S; Kita K
Parasitol Int; 2015 Jun; 64(3):295-300. PubMed ID: 25264100
[TBL] [Abstract][Full Text] [Related]
3. Molecular basis for atovaquone binding to the cytochrome bc1 complex.
Kessl JJ; Lange BB; Merbitz-Zahradnik T; Zwicker K; Hill P; Meunier B; Pálsdóttir H; Hunte C; Meshnick S; Trumpower BL
J Biol Chem; 2003 Aug; 278(33):31312-8. PubMed ID: 12791689
[TBL] [Abstract][Full Text] [Related]
4. Molecular basis for atovaquone resistance in Pneumocystis jirovecii modeled in the cytochrome bc(1) complex of Saccharomyces cerevisiae.
Kessl JJ; Hill P; Lange BB; Meshnick SR; Meunier B; Trumpower BL
J Biol Chem; 2004 Jan; 279(4):2817-24. PubMed ID: 14576156
[TBL] [Abstract][Full Text] [Related]
5. Cytochrome b mutation Y268S conferring atovaquone resistance phenotype in malaria parasite results in reduced parasite bc1 catalytic turnover and protein expression.
Fisher N; Abd Majid R; Antoine T; Al-Helal M; Warman AJ; Johnson DJ; Lawrenson AS; Ranson H; O'Neill PM; Ward SA; Biagini GA
J Biol Chem; 2012 Mar; 287(13):9731-9741. PubMed ID: 22282497
[TBL] [Abstract][Full Text] [Related]
6. Uncovering the molecular mode of action of the antimalarial drug atovaquone using a bacterial system.
Mather MW; Darrouzet E; Valkova-Valchanova M; Cooley JW; McIntosh MT; Daldal F; Vaidya AB
J Biol Chem; 2005 Jul; 280(29):27458-65. PubMed ID: 15917236
[TBL] [Abstract][Full Text] [Related]
7. Resistance mutations reveal the atovaquone-binding domain of cytochrome b in malaria parasites.
Srivastava IK; Morrisey JM; Darrouzet E; Daldal F; Vaidya AB
Mol Microbiol; 1999 Aug; 33(4):704-11. PubMed ID: 10447880
[TBL] [Abstract][Full Text] [Related]
8. Confirmation of emergence of mutations associated with atovaquone-proguanil resistance in unexposed Plasmodium falciparum isolates from Africa.
Happi CT; Gbotosho GO; Folarin OA; Milner D; Sarr O; Sowunmi A; Kyle DE; Milhous WK; Wirth DF; Oduola AM
Malar J; 2006 Oct; 5():82. PubMed ID: 17020611
[TBL] [Abstract][Full Text] [Related]
9. Understanding the mechanism of atovaquone drug resistance in Plasmodium falciparum cytochrome b mutation Y268S using computational methods.
Akhoon BA; Singh KP; Varshney M; Gupta SK; Shukla Y; Gupta SK
PLoS One; 2014; 9(10):e110041. PubMed ID: 25334024
[TBL] [Abstract][Full Text] [Related]
10. Mutations in Plasmodium falciparum cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site.
Korsinczky M; Chen N; Kotecka B; Saul A; Rieckmann K; Cheng Q
Antimicrob Agents Chemother; 2000 Aug; 44(8):2100-8. PubMed ID: 10898682
[TBL] [Abstract][Full Text] [Related]
11. Modeling the molecular basis of atovaquone resistance in parasites and pathogenic fungi.
Kessl JJ; Meshnick SR; Trumpower BL
Trends Parasitol; 2007 Oct; 23(10):494-501. PubMed ID: 17826334
[TBL] [Abstract][Full Text] [Related]
12. Molecular epidemiology of malaria in Cameroon. XVII. Baseline monitoring of atovaquone-resistant Plasmodium falciparum by in vitro drug assays and cytochrome b gene sequence analysis.
Basco LK
Am J Trop Med Hyg; 2003 Aug; 69(2):179-83. PubMed ID: 14506774
[TBL] [Abstract][Full Text] [Related]
13. Structural analysis of atovaquone-inhibited cytochrome bc1 complex reveals the molecular basis of antimalarial drug action.
Birth D; Kao WC; Hunte C
Nat Commun; 2014 Jun; 5():4029. PubMed ID: 24893593
[TBL] [Abstract][Full Text] [Related]
14. Mutations in cytochrome b resulting in atovaquone resistance are associated with loss of fitness in Plasmodium falciparum.
Peters JM; Chen N; Gatton M; Korsinczky M; Fowler EV; Manzetti S; Saul A; Cheng Q
Antimicrob Agents Chemother; 2002 Aug; 46(8):2435-41. PubMed ID: 12121915
[TBL] [Abstract][Full Text] [Related]
15. Probing binding determinants in center P of the cytochrome bc(1) complex using novel hydroxy-naphthoquinones.
Hughes LM; Covian R; Gribble GW; Trumpower BL
Biochim Biophys Acta; 2010 Jan; 1797(1):38-43. PubMed ID: 19660431
[TBL] [Abstract][Full Text] [Related]
16. Plasmodium chabaudi chabaudi malaria parasites can develop stable resistance to atovaquone with a mutation in the cytochrome b gene.
Afonso A; Neto Z; Castro H; Lopes D; Alves AC; Tomás AM; Rosário VD
Malar J; 2010 May; 9():135. PubMed ID: 20492669
[TBL] [Abstract][Full Text] [Related]
17. Saccharomyces cerevisiae-based mutational analysis of the bc1 complex Qo site residue 279 to study the trade-off between atovaquone resistance and function.
Song Z; Clain J; Iorga BI; Yi Z; Fisher N; Meunier B
Antimicrob Agents Chemother; 2015 Jul; 59(7):4053-8. PubMed ID: 25918152
[TBL] [Abstract][Full Text] [Related]
18. Menoctone Resistance in Malaria Parasites Is Conferred by M133I Mutations in Cytochrome
Blake LD; Johnson ME; Siegel SV; McQueen A; Iyamu ID; Shaikh AK; Shultis MW; Manetsch R; Kyle DE
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28584157
[TBL] [Abstract][Full Text] [Related]
19. Role of the evolutionarily conserved cytochrome b tryptophan 142 in the ubiquinol oxidation catalyzed by the bc1 complex in the yeast Saccharomyces cerevisiae.
Bruel C; di Rago JP; Slonimski PP; Lemesle-Meunier D
J Biol Chem; 1995 Sep; 270(38):22321-8. PubMed ID: 7673215
[TBL] [Abstract][Full Text] [Related]
20. Decoding the Molecular Effects of Atovaquone Linked Resistant Mutations on
Chebon-Bore L; Sanyanga TA; Manyumwa CV; Khairallah A; Tastan Bishop Ö
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
